SAN FRANCISCO, February 10, 2017 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today, with great sadness, announced the death of biotechnology legend Dr. Joseph Rubinfeld, who was an independent director of the Company. Dr. Rubinfeld is survived by his wife, Loretta, and children Bonnie, Randee, Susan and Steven and their respective families.
"Dr. Rubinfeld, a co-founder of Amgen Inc., represented the best of the biotechnology industry. He was pragmatic, brilliant, honest and caring and always focused on the needs of patients" said Dr. John Commissiong, Chief Scientific Officer at Amarantus. "Immediately prior to his passing, Dr. Joe was selflessly working very hard to help turn Amarantus around. We will honor his memory by accelerating that effort to the best of our abilities."
Obituary of Dr. Joe Rubinfeld: http://www.oakmontmortuary.com/book-of-memories/2807770/Rubinfeld-Joseph/obituary.php
Joseph Rubinfeld
Resident of Danville, CA
October 24, 1932 - December 26, 2016
Joseph "Dr. Joe" Rubinfeld, a resident of Danville, passed away unexpectedly on December 26, 2016, at his home at the age of 84. Joe was born on October 24, 1932 in Brooklyn, New York to Mechel and Mary Rubinfeld. He married his wife and soul mate Loretta Rubinfeld on March 1, 1958.
Joe attended City College of New York before attending Columbia University for graduate school where he earned a Ph.D. in Organic Chemistry. Over a career that spanned more than 60 years, Joe was instrumental in discoveries that truly changed the world.
Some of his achievements include invention of 10-second Polaroid film and the biodegradable detergent formula used in dishwashing detergents. For saving the Great Lakes with his biodegradable detergent formula, Joe was awarded the Commonwealth Award for Invention in 1985.
Joe was also active in the biotechnology and medical fields. His inventions, including the development of the antibiotics Amoxicillin and Cefadroxil, were directly responsible for saving millions of lives.
While his passion was science and invention, he also had a passion for business. In 1980, he co-founded Amgen, which would become the world's largest biotechnology company. Later in his career, he founded SuperGen, Inc. and then JJ Pharma, Inc. He was active on the corporate and scientific advisory boards of multiple other pharmaceutical companies. He loved working and inventing. He retired once but did not like it because as he said, "there's only so many times you can go to Hawaii or Europe."
Joe is survived by his loving wife of 58 years, Loretta; his son Steven and his wife Kathleen of Danville, his daughter Susan and her husband Joseph Iovino of Danville, his daughter Randee and her husband Kevin Rolens of Danville, and his daughter Bonnee. He is also survived by 10 grandchildren, 2 great grandchildren, his brother Julius Rubinfeld and his wife Leslie, sister Rosalyn Axelrod, and a large and loving extended family.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered from the Company's proprietary discovery engine PhenoGuard. AMBS also received 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact: Ascendant Partners, LLC Fred Sommer +1-732-410-9810 [email protected]
SOURCE Amarantus BioScience Holdings, Inc.
Advertisement
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today, with great sadness, announced the death of biotechnology legend Dr. Joseph Rubinfeld, who was an independent director of the Company. Dr. Rubinfeld is survived by his wife, Loretta, and children Bonnie, Randee, Susan and Steven and their respective families.
Advertisement
"Dr. Rubinfeld, a co-founder of Amgen Inc., represented the best of the biotechnology industry. He was pragmatic, brilliant, honest and caring and always focused on the needs of patients" said Dr. John Commissiong, Chief Scientific Officer at Amarantus. "Immediately prior to his passing, Dr. Joe was selflessly working very hard to help turn Amarantus around. We will honor his memory by accelerating that effort to the best of our abilities."
Obituary of Dr. Joe Rubinfeld: http://www.oakmontmortuary.com/book-of-memories/2807770/Rubinfeld-Joseph/obituary.php
Joseph Rubinfeld
Resident of Danville, CA
October 24, 1932 - December 26, 2016
Joseph "Dr. Joe" Rubinfeld, a resident of Danville, passed away unexpectedly on December 26, 2016, at his home at the age of 84. Joe was born on October 24, 1932 in Brooklyn, New York to Mechel and Mary Rubinfeld. He married his wife and soul mate Loretta Rubinfeld on March 1, 1958.
Joe attended City College of New York before attending Columbia University for graduate school where he earned a Ph.D. in Organic Chemistry. Over a career that spanned more than 60 years, Joe was instrumental in discoveries that truly changed the world.
Some of his achievements include invention of 10-second Polaroid film and the biodegradable detergent formula used in dishwashing detergents. For saving the Great Lakes with his biodegradable detergent formula, Joe was awarded the Commonwealth Award for Invention in 1985.
Joe was also active in the biotechnology and medical fields. His inventions, including the development of the antibiotics Amoxicillin and Cefadroxil, were directly responsible for saving millions of lives.
While his passion was science and invention, he also had a passion for business. In 1980, he co-founded Amgen, which would become the world's largest biotechnology company. Later in his career, he founded SuperGen, Inc. and then JJ Pharma, Inc. He was active on the corporate and scientific advisory boards of multiple other pharmaceutical companies. He loved working and inventing. He retired once but did not like it because as he said, "there's only so many times you can go to Hawaii or Europe."
Joe is survived by his loving wife of 58 years, Loretta; his son Steven and his wife Kathleen of Danville, his daughter Susan and her husband Joseph Iovino of Danville, his daughter Randee and her husband Kevin Rolens of Danville, and his daughter Bonnee. He is also survived by 10 grandchildren, 2 great grandchildren, his brother Julius Rubinfeld and his wife Leslie, sister Rosalyn Axelrod, and a large and loving extended family.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered from the Company's proprietary discovery engine PhenoGuard. AMBS also received 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact: Ascendant Partners, LLC Fred Sommer +1-732-410-9810 [email protected]
SOURCE Amarantus BioScience Holdings, Inc.
